Limits...
Four-year outcomes with third-generation centrifugal left ventricular assist devices in an era of restricted transplantation.

Özalp F, Bhagra S, Bhagra C, Butt T, Ramesh B, Robinson-Smith N, Wrightson N, Parry G, Griselli M, Hasan A, Schueler S, MacGowan GA - Eur J Cardiothorac Surg (2014)

Bottom Line: Older age and more acute INTERMACS groups were significantly related to reduced survival within the first 90 days (P = 0.030 and 0.010, respectively).Poor preoperative right ventricular (RV) function had a negative effect on survival after 1 year (P = 0.009), though not earlier.Only 14 of 102 patients were transplanted at a median of 334 ± 347 days, and only 3 were transplanted within the first 6 months.

View Article: PubMed Central - PubMed

Affiliation: Departments of Cardiothoracic Surgery and Cardiopulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Show MeSH

Related in: MedlinePlus

The timeline of HeartWare® VAD (HVAD) thromboses and number of 6 months new HVAD thromboses, with corresponding changes in the anticoagulation and antiplatelet management noted. Each year is divided into the first 6 months (a) and second 6 months (b). After 2012, a standard dose of aspirin 300 mg daily was introduced and subsequent rates of new HVAD thromboses apparently decreased. INR: international normalized ratio.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4128784&req=5

EZU258F6: The timeline of HeartWare® VAD (HVAD) thromboses and number of 6 months new HVAD thromboses, with corresponding changes in the anticoagulation and antiplatelet management noted. Each year is divided into the first 6 months (a) and second 6 months (b). After 2012, a standard dose of aspirin 300 mg daily was introduced and subsequent rates of new HVAD thromboses apparently decreased. INR: international normalized ratio.

Mentions: The timeline of the changes in the anticoagulation regime relative to the incidence of new VAD thromboses for HeartWare VADs only (divided into 6 monthly intervals noted as ‘a’ and ‘b’) is shown in Fig. 6. During the study period, there has been a change in the design of the HeartWare VAD inflow cannula in the form of a sintered area on the outer side facing the ventricle cavity to encourage epithelialisation that would reduce thrombus formation. The first of these sintered devices was implanted in September 2011 in this series. This had no significant antithrombotic effect in our cohort (P = NS, data not shown).Figure 6:


Four-year outcomes with third-generation centrifugal left ventricular assist devices in an era of restricted transplantation.

Özalp F, Bhagra S, Bhagra C, Butt T, Ramesh B, Robinson-Smith N, Wrightson N, Parry G, Griselli M, Hasan A, Schueler S, MacGowan GA - Eur J Cardiothorac Surg (2014)

The timeline of HeartWare® VAD (HVAD) thromboses and number of 6 months new HVAD thromboses, with corresponding changes in the anticoagulation and antiplatelet management noted. Each year is divided into the first 6 months (a) and second 6 months (b). After 2012, a standard dose of aspirin 300 mg daily was introduced and subsequent rates of new HVAD thromboses apparently decreased. INR: international normalized ratio.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4128784&req=5

EZU258F6: The timeline of HeartWare® VAD (HVAD) thromboses and number of 6 months new HVAD thromboses, with corresponding changes in the anticoagulation and antiplatelet management noted. Each year is divided into the first 6 months (a) and second 6 months (b). After 2012, a standard dose of aspirin 300 mg daily was introduced and subsequent rates of new HVAD thromboses apparently decreased. INR: international normalized ratio.
Mentions: The timeline of the changes in the anticoagulation regime relative to the incidence of new VAD thromboses for HeartWare VADs only (divided into 6 monthly intervals noted as ‘a’ and ‘b’) is shown in Fig. 6. During the study period, there has been a change in the design of the HeartWare VAD inflow cannula in the form of a sintered area on the outer side facing the ventricle cavity to encourage epithelialisation that would reduce thrombus formation. The first of these sintered devices was implanted in September 2011 in this series. This had no significant antithrombotic effect in our cohort (P = NS, data not shown).Figure 6:

Bottom Line: Older age and more acute INTERMACS groups were significantly related to reduced survival within the first 90 days (P = 0.030 and 0.010, respectively).Poor preoperative right ventricular (RV) function had a negative effect on survival after 1 year (P = 0.009), though not earlier.Only 14 of 102 patients were transplanted at a median of 334 ± 347 days, and only 3 were transplanted within the first 6 months.

View Article: PubMed Central - PubMed

Affiliation: Departments of Cardiothoracic Surgery and Cardiopulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Show MeSH
Related in: MedlinePlus